EXEL Exelixis, Inc.
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances) · Market cap $15.4B · $58.39 on 2026-10-02
Buy (Payback/Ten Cap)Tier CDetailed (TTM)
Price moves
1 week0%
1 month-1%
3 months5%
6 months33%
YTD33%
1 year46%
Off 52w high-5%
52w range$34–$61
Price history
Show year-end prices
| Year | Close |
|---|---|
| 2016 | $14.91 |
| 2017 | $30.4 |
| 2018 | $19.67 |
| 2019 | $17.62 |
| 2020 | $20.07 |
| 2021 | $18.28 |
| 2022 | $16.04 |
| 2023 | $23.99 |
| 2024 | $33.3 |
| 2025 | $43.83 |
| 2026-10-02 (latest) | $58.39 |
Buy (MOS)
$40
$40
Ten Cap
$44
$44
Payback Time
$70
$70
Sticker
$80
$80
Price
$58
$58
Valuation
| Buy (MOS) 50% of Sticker | $39.97 | -32% |
|---|---|---|
| Ten Cap 10× owner earnings | $44.50 | -24% |
| Payback Time 8-year FCF payback | $70.24 | 20% |
| Sticker Rule #1 intrinsic value | $79.94 | 37% |
| Windage growth g | 15.0% | |
| Future P/E (min 2g, 10y median) | 25.1× | |
| P/E · 10y median | 18.4× | 25.1× |
| EPS TTM 2026-07-03 | $3.18 | |
| FCF yield | 7.6% | |
| Revenue · net income last FY | $2.3B | $783M |
Big Five 9/15 tests ≥10%
| 10y | 5y | 1y | |
|---|---|---|---|
| ROIC | 18% | 15% | 32% |
| Sales growth | 51% | 19% | 7% |
| EPS growth | – | 51% | 58% |
| BVPS growth | – | 5% | 1% |
| OCF growth | – | 33% | 26% |
| Debt payoff (yrs of FCF) | 0.0 |
Events
13D: SCHEDULE 13D/A 2026-08-14; 8-K: 2026-09-11: 8.01 Other event; next report ~2026-11-04
Next report ≈ 2026-11-04 · SEC filings ·Yahoo Finance